CLNN earnings date and last-quarter result: next report 2026-08-13, last quarter miss, P/E -1.79. Updated 2026-07-23.
Clene (CLNN) Research Hub
Clene (CLNN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 3.84 USD (-1.03%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.79, market cap 0.06B. This hub links to the full technical, earnings and options research available for CLNN.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 3.84 USD (-1.03%) |
| 52-week range | 3.02 USD – 6.46 USD |
| Trend regime | Range |
| 14-day RSI | 49.1 (Neutral) |
| Trailing P/E | -1.79 |
| Market cap | 0.06B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for CLNN
Covered Call on CLNN: how it works, illustrative setup around the real 3.84 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CLNN: how it works, illustrative setup around the real 3.84 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CLNN: how it works, illustrative setup around the real 3.84 USD price, max profit/loss, breakeven and when to use it. Educational.
CLNN technical analysis: range, last 3.84 USD, RSI 49.1, 52w range 3.02 USD–6.46 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is CLNN in?
Clene (CLNN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CLNN in an uptrend or downtrend?
As of 2026-10-26, CLNN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CLNN's trailing P/E ratio?
CLNN's trailing P/E is -1.79, with a market cap of 0.06B. See the earnings research page for full valuation detail.
When does CLNN next report earnings?
CLNN is next scheduled to report earnings on 2026-08-13.